Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical vs Matched Unrelated Donor Transplant in Acute Leukemia (HaploMUD)
NCT04232241Phase 2Active, not recruiting
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Nov 2019
- Primary completion
- Nov 2026
- Modality
- Stem Cell Therapies
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of allogeneic hematopoietic stem cells in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Relapse incidence at two years at 2 years. Started Nov 2019; status: active, not recruiting.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04232241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232241.